Wells Fargo’s Carisma Therapeutics CARM Stock Holding History

Wells Fargo’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10,690	Closed	-$61K	–	6062
2018 Q4	$61K	Buy	+10,690	New	+$341K	﹤0.01%	5457

Other funds holding CARM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TOTUOP

Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo's CARM Position: Q2 2024 in Review

Wells Fargo sold out of Carisma Therapeutics (CARM) in Q2 2024, closing a stake of 19,371 shares — an estimated $44K sold.

Wells Fargo first reported a position in CARM in Q2 2014 and held it in 28 quarters. The position peaked at $1.14M in Q1 2021. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2024.

Wells Fargo reported no remaining Carisma Therapeutics position as of Q2 2024 after selling out during the quarter.
Wells Fargo sold 19,371 Carisma Therapeutics shares in Q2 2024, an estimated $44K.
Wells Fargo first reported a position in Carisma Therapeutics in Q2 2014 and held it in 28 quarters.
Wells Fargo's Carisma Therapeutics position peaked at $1.14M in Q1 2021.
53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.